Zacks Research Has Strong Estimate for Glaukos Q4 Earnings

Glaukos Co. (NYSE:GKOS) – Analysts at Zacks Research boosted their Q4 2026 earnings per share estimates for shares of Glaukos in a research note issued on Thursday, March 13th. Zacks Research analyst I. Bandyopadhyay now anticipates that the medical instruments supplier will post earnings of $0.06 per share for the quarter, up from their prior estimate of $0.03. The consensus estimate for Glaukos’ current full-year earnings is ($1.08) per share. Zacks Research also issued estimates for Glaukos’ FY2027 earnings at $0.82 EPS.

Several other research firms also recently commented on GKOS. Needham & Company LLC increased their target price on Glaukos from $149.00 to $176.00 and gave the company a “buy” rating in a research report on Friday, February 21st. Citigroup upgraded shares of Glaukos from a “neutral” rating to a “buy” rating and upped their price target for the company from $132.00 to $162.00 in a research report on Wednesday, December 11th. BTIG Research lifted their price target on shares of Glaukos from $140.00 to $149.00 and gave the stock a “buy” rating in a report on Tuesday, November 26th. Stephens raised Glaukos to a “strong-buy” rating in a report on Monday, December 2nd. Finally, Truist Financial upped their price target on Glaukos from $152.00 to $185.00 and gave the company a “buy” rating in a research report on Wednesday, December 18th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $163.25.

Glaukos Stock Up 0.9 %

Shares of NYSE:GKOS opened at $103.12 on Monday. The company has a debt-to-equity ratio of 0.19, a quick ratio of 4.71 and a current ratio of 5.54. Glaukos has a 52-week low of $85.04 and a 52-week high of $163.71. The company has a market capitalization of $5.83 billion, a PE ratio of -35.93 and a beta of 0.99. The company has a fifty day moving average of $139.82 and a 200-day moving average of $137.49.

Glaukos (NYSE:GKOS) last issued its earnings results on Thursday, February 20th. The medical instruments supplier reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.02). Glaukos had a negative return on equity of 16.53% and a negative net margin of 39.04%. The business had revenue of $105.50 million for the quarter, compared to analyst estimates of $100.72 million.

Insider Activity

In other Glaukos news, Director Gilbert H. Kliman sold 10,000 shares of the stock in a transaction that occurred on Friday, December 20th. The stock was sold at an average price of $150.28, for a total value of $1,502,800.00. Following the transaction, the director now owns 32,336 shares in the company, valued at approximately $4,859,454.08. This represents a 23.62 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Joseph E. Gilliam sold 3,328 shares of the business’s stock in a transaction that occurred on Friday, December 20th. The shares were sold at an average price of $149.85, for a total value of $498,700.80. Following the sale, the chief operating officer now owns 102,169 shares of the company’s stock, valued at approximately $15,310,024.65. This represents a 3.15 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 16,744 shares of company stock worth $2,504,131 in the last quarter. 6.40% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. IFP Advisors Inc purchased a new position in shares of Glaukos during the fourth quarter valued at approximately $43,000. Asset Planning Inc purchased a new position in Glaukos during the 4th quarter worth $90,000. CoreCap Advisors LLC grew its stake in shares of Glaukos by 36.4% in the 4th quarter. CoreCap Advisors LLC now owns 750 shares of the medical instruments supplier’s stock worth $112,000 after acquiring an additional 200 shares in the last quarter. Harvest Fund Management Co. Ltd raised its holdings in shares of Glaukos by 2,263.2% in the third quarter. Harvest Fund Management Co. Ltd now owns 898 shares of the medical instruments supplier’s stock valued at $117,000 after purchasing an additional 860 shares during the last quarter. Finally, Picton Mahoney Asset Management bought a new position in shares of Glaukos during the fourth quarter valued at about $125,000. 99.04% of the stock is owned by institutional investors.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.